[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MA22150A1 - Procede de preparation de compositions destinees a engendrer des effets therapeutiques synergiques - Google Patents

Procede de preparation de compositions destinees a engendrer des effets therapeutiques synergiques

Info

Publication number
MA22150A1
MA22150A1 MA22420A MA22420A MA22150A1 MA 22150 A1 MA22150 A1 MA 22150A1 MA 22420 A MA22420 A MA 22420A MA 22420 A MA22420 A MA 22420A MA 22150 A1 MA22150 A1 MA 22150A1
Authority
MA
Morocco
Prior art keywords
generate
therapeutic effects
compositions intended
preparing compositions
synergic
Prior art date
Application number
MA22420A
Other languages
English (en)
Inventor
A Fossa A
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24080550&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA22150(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of MA22150A1 publication Critical patent/MA22150A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA22420A 1990-05-11 1991-05-08 Procede de preparation de compositions destinees a engendrer des effets therapeutiques synergiques MA22150A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US52236090A 1990-05-11 1990-05-11

Publications (1)

Publication Number Publication Date
MA22150A1 true MA22150A1 (fr) 1991-12-31

Family

ID=24080550

Family Applications (1)

Application Number Title Priority Date Filing Date
MA22420A MA22150A1 (fr) 1990-05-11 1991-05-08 Procede de preparation de compositions destinees a engendrer des effets therapeutiques synergiques

Country Status (34)

Country Link
US (2) US6900234B1 (fr)
EP (1) EP0527879B1 (fr)
JP (2) JPH0729938B2 (fr)
KR (1) KR970005839B1 (fr)
CN (7) CN1065140C (fr)
AP (1) AP240A (fr)
AT (1) ATE148632T1 (fr)
AU (1) AU653724B2 (fr)
BG (1) BG61831B1 (fr)
BR (1) BR9106438A (fr)
CA (1) CA2081564C (fr)
DE (1) DE69124598T2 (fr)
DK (1) DK0527879T3 (fr)
EG (1) EG19648A (fr)
ES (1) ES2097208T3 (fr)
GR (1) GR3022997T3 (fr)
GT (1) GT199100032A (fr)
HK (1) HK1094148A1 (fr)
HU (1) HU227346B1 (fr)
IE (1) IE911592A1 (fr)
IL (1) IL98055A (fr)
IS (1) IS2042B (fr)
MA (1) MA22150A1 (fr)
MY (1) MY114347A (fr)
NO (1) NO924321L (fr)
NZ (1) NZ238118A (fr)
PE (1) PE30891A1 (fr)
PT (1) PT97615B (fr)
RO (1) RO115786B1 (fr)
RU (1) RU2147875C1 (fr)
TW (1) TW203553B (fr)
WO (1) WO1991017771A1 (fr)
YU (1) YU49094B (fr)
ZA (1) ZA913539B (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2081564C (fr) * 1990-05-11 1998-02-03 Anthony Andrea Fossa Compositions et methodes therapeutiques synergiques
EP0629408A1 (fr) * 1993-06-16 1994-12-21 LABORATOIRES MERCK, SHARP & DOHME-CHIBRET Combination d'inhibiteurs ACE et d'antagonistes AII
DE4340437C1 (de) * 1993-11-27 1995-05-24 Karla Dr Lehmann Verwendung von Lithiumverbindungen zur Behandlung von Herzinsuffizienz einschließlich ihrer Folgeerkrankungen
WO1996031234A1 (fr) * 1995-04-07 1996-10-10 Novartis Ag Compositions de combinaison contenant benazeprile ou benazeprilat et valsartane
AU716519B2 (en) * 1995-06-30 2000-02-24 Laboratoires Merck Sharp & Dohme - Chibret Snc Method of treating renal disease using an ace inhibitor and an A II antagonist
CZ297941B6 (cs) 1996-04-05 2007-05-02 Takeda Pharmaceutical Company Limited Farmaceutický prípravek obsahující slouceninu s antagonickým úcinkem k angiotensinu II
WO1997049392A1 (fr) * 1996-06-24 1997-12-31 Merck & Co., Inc. Composition a base d'enalapril et de losartan
US6087386A (en) * 1996-06-24 2000-07-11 Merck & Co., Inc. Composition of enalapril and losartan
US6248724B1 (en) 1997-09-25 2001-06-19 University Of Florida Antisense oligonucleotide compositions targeted to angiotensin converting enzyme MRNA and methods of use
BR9814422A (pt) * 1997-12-23 2000-10-10 Warner Lambert Co Combinações de inibidor de ace - inibidor de mmp
US6087343A (en) * 1998-09-14 2000-07-11 University Of Florida Antisense oligonucleotides targeted to β-1 adrenoceptor and methods of use
US6387894B1 (en) * 1999-06-11 2002-05-14 Pfizer Inc. Use of CRF antagonists and renin-angiotensin system inhibitors
US8168616B1 (en) * 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
EP1531879A1 (fr) * 2002-06-28 2005-05-25 Novartis AG Utilisation de composes organiques
SI2368553T1 (sl) 2003-04-08 2015-05-29 Progenics Pharmaceuticals, Inc. Farmacevtske formulacije, vsebujoče metilnatrekson
US20040265238A1 (en) 2003-06-27 2004-12-30 Imtiaz Chaudry Inhalable formulations for treating pulmonary hypertension and methods of using same
EP2248520A3 (fr) * 2004-10-08 2010-11-17 Novartis AG Utilisation d'inhibiteurs de rénine pour la prévention ou le traitement du dysfonctionnement diastolique ou de la cardiopathie diastolique
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
CN104248763A (zh) * 2005-03-07 2014-12-31 芝加哥大学 阿片样物质拮抗剂用于减少内皮细胞增殖和迁移的用途
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
TW200817048A (en) * 2006-09-08 2008-04-16 Wyeth Corp Dry powder compound formulations and uses thereof
CL2007002689A1 (es) 2006-09-18 2008-04-18 Vitae Pharmaceuticals Inc Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras.
AU2008233133B2 (en) 2007-03-29 2014-03-27 Progenics Pharmaceuticals, Inc. Crystal forms of (R) -N-methylnaltrexone bromide and uses thereof
PL2139890T3 (pl) 2007-03-29 2014-11-28 Wyeth Llc Antagoniści obwodowych receptorów opioidowych i ich zastosowania
PE20130480A1 (es) 2007-03-29 2013-05-08 Progenics Pharm Inc Compuestos heterociclicos como antagonistas del receptor opioide periferico
WO2009099411A1 (fr) 2008-02-06 2009-08-13 Progenics Pharmaceuticals, Inc. Préparation et utilisation de (r),(r)-2,2'-bis-méthylnaltrexone
CA2719134C (fr) 2008-03-21 2015-06-30 The University Of Chicago Traitement avec des antagonistes des opioides et des inhibiteurs mtor
CA2676881C (fr) 2008-09-30 2017-04-25 Wyeth Antagonistes de recepteurs opioides peripheriques, et leurs utilisations
AR077692A1 (es) 2009-08-06 2011-09-14 Vitae Pharmaceuticals Inc Sales de 2-((r)-(3-clorofenil) ((r)-1-((s) -2-(metilamino)-3-((r)-tetrahidro-2h-piran-3-il) propilcarbamoil) piperidin -3-il) metoxi) etilcarbamato de metilo
CN102423483A (zh) * 2011-11-24 2012-04-25 西北农林科技大学 一种复方雷米普利纳米乳抗高血压药物
CN114032273B (zh) * 2021-11-17 2024-02-02 山东省科学院生物研究所 一种多功能西洋参水解肽及其制备方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US324377A (en) * 1885-08-18 Roller-skate
US4046889A (en) * 1976-02-13 1977-09-06 E. R. Squibb & Sons, Inc. Azetidine-2-carboxylic acid derivatives
IL58849A (en) * 1978-12-11 1983-03-31 Merck & Co Inc Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them
JPS5671074A (en) * 1979-11-12 1981-06-13 Takeda Chem Ind Ltd 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative
US4749688A (en) 1986-06-20 1988-06-07 Schering Corporation Use of neutral metalloendopeptidase inhibitors in the treatment of hypertension
CA1334092C (fr) 1986-07-11 1995-01-24 David John Carini Imidazoles bloquant les recepteurs de l'angiotensine ii
US4814342A (en) 1986-10-31 1989-03-21 Pfizer Inc. Nor-statine and nor-cyclostatine polypeptides
US4895834A (en) * 1986-12-15 1990-01-23 Warner-Lambert Company Renin inhibitors III
US4962105A (en) 1987-10-19 1990-10-09 Ciba-Geigy Corporation Potentiation of antihypertensive effect of ace inhibitors
CA1338238C (fr) * 1988-01-07 1996-04-09 David John Carini Imidazoles bloquant les recepteurs de l'angiotensine ii et combinaisons de ces imidazoles avec des diuretiques et des anti-inflammatoires non steroidiens
US5015651A (en) 1988-01-07 1991-05-14 E. I. Du Pont De Nemours And Company Treatment of hypertension with 1,2,4-angiotensin II antagonists
US4880804A (en) * 1988-01-07 1989-11-14 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking benzimidazoles
IL91780A (en) 1988-10-04 1995-08-31 Abbott Lab History of the amine of the xenon-preventing xanine acid, the process for their preparation and the pharmaceutical preparations containing them
CA2081564C (fr) * 1990-05-11 1998-02-03 Anthony Andrea Fossa Compositions et methodes therapeutiques synergiques

Also Published As

Publication number Publication date
MY114347A (en) 2002-10-31
CN1056426A (zh) 1991-11-27
JP2635291B2 (ja) 1997-07-30
CA2081564C (fr) 1998-02-03
CN1824315A (zh) 2006-08-30
IE911592A1 (en) 1991-11-20
EG19648A (en) 1995-09-30
YU81991A (sh) 1994-06-24
JPH0729938B2 (ja) 1995-04-05
EP0527879A1 (fr) 1993-02-24
IS2042B (is) 2005-09-15
BR9106438A (pt) 1993-05-18
TW203553B (fr) 1993-04-11
AU653724B2 (en) 1994-10-13
PE30891A1 (es) 1991-11-27
JPH0748280A (ja) 1995-02-21
CN1879884A (zh) 2006-12-20
IS3703A7 (is) 1991-11-12
CN101156949A (zh) 2008-04-09
AP9100258A0 (en) 1991-07-31
HU9203522D0 (en) 1993-01-28
US6900234B1 (en) 2005-05-31
NZ238118A (en) 1997-06-24
KR970005839B1 (ko) 1997-04-21
AU7859191A (en) 1991-12-10
CN1065140C (zh) 2001-05-02
BG61831B1 (bg) 1998-07-31
PT97615A (pt) 1992-03-31
ZA913539B (en) 1992-12-30
YU49094B (sh) 2003-12-31
IL98055A0 (en) 1992-06-21
DK0527879T3 (da) 1997-07-14
US6716875B1 (en) 2004-04-06
JPH05505618A (ja) 1993-08-19
NO924321D0 (no) 1992-11-10
CN1824315B (zh) 2011-01-12
HU227346B1 (en) 2011-04-28
CN1502370A (zh) 2004-06-09
WO1991017771A1 (fr) 1991-11-28
EP0527879B1 (fr) 1997-02-05
ATE148632T1 (de) 1997-02-15
CN1915428A (zh) 2007-02-21
ES2097208T3 (es) 1997-04-01
NO924321L (no) 1993-01-08
RU2147875C1 (ru) 2000-04-27
RO115786B1 (ro) 2000-06-30
PT97615B (pt) 1998-08-31
DE69124598T2 (de) 1997-05-28
IL98055A (en) 1996-10-31
CN100358578C (zh) 2008-01-02
AP240A (en) 1993-02-18
DE69124598D1 (de) 1997-03-20
CA2081564A1 (fr) 1991-11-12
GT199100032A (es) 1992-10-31
HUT62804A (en) 1993-06-28
GR3022997T3 (en) 1997-07-30
BG97068A (bg) 1993-12-24
CN1307901A (zh) 2001-08-15
HK1094148A1 (en) 2007-03-23

Similar Documents

Publication Publication Date Title
MA22150A1 (fr) Procede de preparation de compositions destinees a engendrer des effets therapeutiques synergiques
PT71436B (en) Process for preparing pharmaceutical compositions
GB2122085B (en) A process for the preparation of activated pharmaceutical compositions
GB8810193D0 (en) Detergent compositions & process for preparing them
PT73065A (en) Process for preparing pharmaceutical compositions having improved release properties
NZ191711A (en) Lipid compositions containing a digalactosyl derivative for use in pharmaceutical compositions
IL95241A (en) Fertilizer compositions for administering ionic metal microelements to plant roots
IL93579A0 (en) Apparatus for rapidly preparing to obtain biosignals
BE873772A (fr) Procede de preparation de compositions detergentes
HK47894A (en) Process for preparing detergent compositions
LU80459A1 (fr) Procede de preparation de compositions tensio-actives cationiques
RO79525A (fr) Procede de preparation d'un vaccin contre l'influenza
GB9116289D0 (en) Improvements relating to gaming machines
PT70287A (en) Process for obtaining denture cleansing compositions
GB2134867B (en) Feeder e g for soap tablets to wrapping machine
HUT34122A (en) Process for preparing synrtgetic pharmaceutical compositions
PT76999A (en) Process for preparing pharmaceutical compositions having analgesic activity
HUT36099A (en) Pharmaceutical compositions containing process for preparing 4-aroyl-imidazol-2-one derivatives
PT72727A (en) Process for preparing pharmaceutical compositions
HUT44942A (en) Process for producing pharmaceutical compositions for inhibiting thromogenesis
PT75504A (en) Process for preparing pharmaceutical compositions
HU208085B (en) Process for producing pharmaceutical compositions comprising iron
HUT58519A (en) Process for producing pharmaceutical composition suitable for treating alzheimer disease
PT74056B (en) Process for preparing pharmaceutical compositions containing 1--(2-3'-carboxypropionil oxyethyl)-2-methyl-5-nitroimidazole as active therapeutic agent against diseases caused by anaerobic germs
BE870287A (fr) Procede de preparation de compositions bitumes-polymeres acryliques-elastomeres